Appointment enhances leadership team with a focus on strategic planning and business development expertise
CINCINNATI – October 18, 2022 – CinRx Pharma, a mosaic of biotechnology companies accelerating transformational new medicines to patients, announced today that Gavin Samuels, M.D., M.B.A has assumed the role of Chief Business Officer. In his new role, Gavin will be responsible for leading corporate, strategic and business development and transactions for the CinRx portfolio.
“CinRx’s bold and important mission to overcome historic drug development hurdles and improve the drug development process is only possible through our dedicated and highly-experienced team, including Gavin,” said Jon Isaacsohn, M.D., FACC, Chief Executive Officer of CinRx Pharma. “Gavin’s strategic input and expertise has been instrumental in our success to date, and it’s my pleasure to announce him officially joining our C-suite where he can further extend his leadership and guide the next generation of CinRx.”
“Leadership to me is inspiring a team to reach their full potential through drive, passion and clear, audacious goals. The CinRx leadership team is completely aligned with this philosophy,” said Gavin. “I’m confident that alongside our experienced team of life science leaders, we will realize our mission of accelerating high-potential medicines as quickly and efficiently as possible from the lab to patients in need.”
Gavin joins CinRx with 25 years of experience across large pharma and emerging biotech settings in various functions including business development, private and public financing, investor relations, and strategy. As a former physician, his focus and passion are developing high potential medicines and care for patients in need. Before joining CinRx, he served as Global Head of Strategy & Growth Initiatives at Lonza Biologics, where he oversaw strategic development and implementation of new business models and strategies. Prior to this, Gavin held transactional, corporate venture and business development positions at Merck, Pfizer and Teva Pharmaceuticals.
About CinRx Pharma:
CinRx is a mosaic of biotechnology companies supported by a dedicated funding mechanism designed to improve drug development success and accelerate transformational new medicines to patients. By integrating our deep scientific, clinical and operational expertise with a thoughtful portfolio model, we establish the optimal development trajectory – a drug development superhighway. The company’s experienced team ensures high-potential medicines are financially and operationally championed with the most efficient route from the lab to the patient. For more information, please visit www.CinRx.com or follow the company on Twitter and LinkedIn.
Media Contact:
Cassidy McClain
Account Director, Communications
CinRx Contact:
Jason Westerheide
Executive Director, Business Development
